[go: up one dir, main page]

MX2013010475A - Composiciones inmunoterapeuticas de levadura-brachyuri. - Google Patents

Composiciones inmunoterapeuticas de levadura-brachyuri.

Info

Publication number
MX2013010475A
MX2013010475A MX2013010475A MX2013010475A MX2013010475A MX 2013010475 A MX2013010475 A MX 2013010475A MX 2013010475 A MX2013010475 A MX 2013010475A MX 2013010475 A MX2013010475 A MX 2013010475A MX 2013010475 A MX2013010475 A MX 2013010475A
Authority
MX
Mexico
Prior art keywords
levadura
brachyuri
immunotherapeutic compositions
brachyury
compositions
Prior art date
Application number
MX2013010475A
Other languages
English (en)
Other versions
MX350661B (es
Inventor
Claudia Palena
Zhimin Guo
David Apelian
Jeffrey Schlom
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MX2013010475A publication Critical patent/MX2013010475A/es
Publication of MX350661B publication Critical patent/MX350661B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)

Abstract

Se describen composiciones inmunoterapéuticas a base de levadura que comprenden antígenos de Brachyury, y métodos para la prevención y/o tratamientos de cánceres caracterizados por la expresión o sobreexpresión de Brachyury.
MX2013010475A 2011-03-17 2012-03-19 Composiciones inmunoterapeuticas de levadura-brachyuri. MX350661B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161453656P 2011-03-17 2011-03-17
PCT/US2012/029636 WO2012125998A1 (en) 2011-03-17 2012-03-19 Yeast-brachyury immunotherapeutic compositions

Publications (2)

Publication Number Publication Date
MX2013010475A true MX2013010475A (es) 2014-05-28
MX350661B MX350661B (es) 2017-09-13

Family

ID=46831122

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010475A MX350661B (es) 2011-03-17 2012-03-19 Composiciones inmunoterapeuticas de levadura-brachyuri.

Country Status (19)

Country Link
US (5) US9198941B2 (es)
EP (2) EP3238731B1 (es)
JP (4) JP6068368B2 (es)
KR (1) KR102046449B1 (es)
CN (1) CN103648513B (es)
AU (3) AU2012228937B2 (es)
BR (1) BR112013023456B1 (es)
CA (1) CA2835475C (es)
DK (1) DK2685995T3 (es)
ES (1) ES2627979T3 (es)
HK (1) HK1245649A1 (es)
HU (1) HUE033491T2 (es)
IL (1) IL228421B (es)
MX (1) MX350661B (es)
PL (1) PL2685995T3 (es)
PT (1) PT2685995T (es)
RU (2) RU2690180C2 (es)
SG (2) SG10201601913RA (es)
WO (1) WO2012125998A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006479A2 (en) 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
BR112013020425A2 (pt) 2011-02-12 2017-06-13 Globeimmune Inc composições e métodos para o tratamento ou prevenção de infecção por vírus da hepatite b
AU2012228937B2 (en) 2011-03-17 2016-11-03 Globeimmune, Inc. Yeast-Brachyury immunotherapeutic compositions
CN103732250A (zh) 2011-06-14 2014-04-16 全球免疫股份有限公司 基于酵母的治疗或预防丁型肝炎病毒感染的组合物和方法
MX352892B (es) 2011-08-17 2017-12-13 Globeimmune Inc Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas.
KR102103319B1 (ko) 2012-06-26 2020-04-22 바이오디식스, 인크. 면역반응 발생 요법으로 치료하기 위해 암환자들의 선택, 및 선택해제를 위한 질량-스펙트럼법
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
ES2752190T3 (es) * 2012-09-14 2020-04-03 Us Health Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
SG11201507328RA (en) * 2013-03-19 2015-10-29 Globeimmune Inc Yeast-based immunotherapy for chordoma
WO2014160747A2 (en) 2013-03-26 2014-10-02 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
US9725494B2 (en) * 2013-05-17 2017-08-08 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble CD27 (sCD27) and the use thereof
WO2015031778A2 (en) 2013-08-30 2015-03-05 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
CN113419058B (zh) 2014-04-11 2025-04-01 全球免疫股份有限公司 基于酵母的免疫疗法和i型干扰素敏感性
WO2016112195A1 (en) 2015-01-09 2016-07-14 Etubics Corporation Methods and compositions for combination immunotherapy
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
KR102833272B1 (ko) * 2015-08-03 2025-07-10 글로브이뮨 변형된 효모-브라큐리 면역치료학적 조성물
JP7048482B2 (ja) * 2015-08-03 2022-04-05 アメリカ合衆国 Ｂｒａｃｈｙｕｒｙ欠失変異体、Ｂｒａｃｈｙｕｒｙ欠失変異体をコードする非酵母ベクター、及びそれらの使用
AU2017281126A1 (en) 2016-03-24 2018-10-04 Nant Holdings Ip, Llc Sequence arrangements and sequences for neoepitope presentation
WO2017210562A1 (en) * 2016-06-03 2017-12-07 Etubics Corporation Compositions and methods for tumor vaccination using prostate cancer-associated antigens
EP3541400B1 (en) 2016-11-18 2025-05-14 Sanford Burnham Prebys Medical Discovery Institute Gut microbiota and treatment of cancer
IL270132B2 (en) 2017-04-24 2024-12-01 Nantcell Inc Neoepitope vectors and methods for them
EP3668538A4 (en) 2017-08-15 2021-06-16 NantCell, Inc. HANK-CETUXIMAB COMBINATIONS AND PROCEDURES
WO2019222073A1 (en) 2018-05-15 2019-11-21 Globeimmune, Inc. Lysates of recombinant yeast for inducing cellular immune responses
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1036329A (en) 1908-11-19 1912-08-20 Edison Inc Thomas A Phonograph-reproducer.
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
CA2403292C (en) 2000-04-06 2011-02-08 Panacea Pharmaceuticals, Llc Microbial delivery system
WO2002039951A2 (en) 2000-11-15 2002-05-23 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
WO2004058157A2 (en) 2002-12-16 2004-07-15 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
EP2371381A3 (en) 2005-07-11 2012-07-18 Globeimmune, Inc. Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
CN104826102A (zh) 2006-02-02 2015-08-12 全球免疫股份有限公司 用于诱导免疫应答的基于酵母的疫苗
CA2647102A1 (en) 2006-03-27 2007-11-22 Globeimmune, Inc. Ras mutation and compositions and methods related thereto
WO2008097863A2 (en) * 2007-02-02 2008-08-14 Globeimmune, Inc. Methods for producing yeast-based vaccines
JP5596980B2 (ja) * 2007-02-28 2014-10-01 アメリカ合衆国 ブラキュリポリペプチドおよび使用方法
CA2681246A1 (en) 2007-03-19 2008-09-25 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
WO2009042642A2 (en) 2007-09-24 2009-04-02 President And Fellows Of Harvard College Compositions and methods for the treatment and prevention of ulcerative colitis and colon cancer
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
CA2759013C (en) * 2009-04-17 2021-10-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy compositions against cancer and methods
JP5913103B2 (ja) 2009-09-14 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法
EP2547792A4 (en) 2010-03-14 2013-11-27 Globeimmune Inc PHARMACOGENOMIC TREATMENT AND ADAPTATION TO THE RESPONSE OF AN INFECTIOUS DISEASE USING YEAST IMMUNOTHERAPY
WO2012019127A2 (en) * 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
BR112013020425A2 (pt) 2011-02-12 2017-06-13 Globeimmune Inc composições e métodos para o tratamento ou prevenção de infecção por vírus da hepatite b
AU2012228937B2 (en) 2011-03-17 2016-11-03 Globeimmune, Inc. Yeast-Brachyury immunotherapeutic compositions
CN103732250A (zh) 2011-06-14 2014-04-16 全球免疫股份有限公司 基于酵母的治疗或预防丁型肝炎病毒感染的组合物和方法
MX352892B (es) 2011-08-17 2017-12-13 Globeimmune Inc Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas.

Also Published As

Publication number Publication date
NZ616696A (en) 2015-09-25
EP2685995A4 (en) 2014-12-24
US20190374624A1 (en) 2019-12-12
AU2012228937A1 (en) 2013-10-31
RU2017116350A3 (es) 2018-10-17
PT2685995T (pt) 2017-08-09
EP2685995A1 (en) 2014-01-22
JP2017061570A (ja) 2017-03-30
HUE033491T2 (en) 2017-12-28
US20140004135A1 (en) 2014-01-02
HK1245649A1 (en) 2018-08-31
MX350661B (es) 2017-09-13
DK2685995T3 (en) 2017-08-21
IL228421B (en) 2019-02-28
JP6309607B2 (ja) 2018-04-11
KR102046449B1 (ko) 2019-11-19
SG10201601913RA (en) 2016-05-30
JP2014509595A (ja) 2014-04-21
US11938175B2 (en) 2024-03-26
RU2013146324A (ru) 2015-04-27
SG193396A1 (en) 2013-10-30
US9198941B2 (en) 2015-12-01
US10363294B2 (en) 2019-07-30
BR112013023456B1 (pt) 2020-11-17
RU2017116350A (ru) 2018-10-17
CN103648513A (zh) 2014-03-19
KR20140038387A (ko) 2014-03-28
EP3238731A1 (en) 2017-11-01
AU2018202972A1 (en) 2018-05-17
AU2017200715A1 (en) 2017-02-23
ES2627979T3 (es) 2017-08-01
CA2835475C (en) 2020-06-30
CA2835475A1 (en) 2012-09-20
AU2018202972B2 (en) 2019-08-29
JP2018090634A (ja) 2018-06-14
JP2019199484A (ja) 2019-11-21
US11944673B2 (en) 2024-04-02
BR112013023456A2 (pt) 2016-12-06
RU2619850C2 (ru) 2017-05-18
US20170246276A1 (en) 2017-08-31
JP6068368B2 (ja) 2017-01-25
US9623097B2 (en) 2017-04-18
CN103648513B (zh) 2018-10-12
IL228421A0 (en) 2013-12-31
EP3238731B1 (en) 2021-02-17
PL2685995T3 (pl) 2017-10-31
JP6580733B2 (ja) 2019-09-25
US20210106666A1 (en) 2021-04-15
EP2685995B1 (en) 2017-05-03
RU2690180C2 (ru) 2019-05-31
AU2017200715B2 (en) 2018-05-31
US20160106824A1 (en) 2016-04-21
AU2012228937B2 (en) 2016-11-03
WO2012125998A1 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
MX2013010475A (es) Composiciones inmunoterapeuticas de levadura-brachyuri.
MX2014001717A (es) Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas.
CR20140441A (es) Anticuerpos anti-lgr5 e inmunoconjugados
EA201171367A1 (ru) Винилиндазолильные соединения
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
CR20150047A (es) Anticuerpos anti-cd22 e inmunoconjugados
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
WO2014152157A3 (en) Methods and compositions for the generation and use of conformation-specific antibodies
MX373121B (es) Composiciones y metodos para el tratamiento de leucemia.
EA201400178A1 (ru) Лечение рака молочной железы
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
CO7020867A2 (es) Formulaciones de anticuerpo y metodos
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
CR20130138A (es) Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación
IN2014DN09450A (es)
CO6761388A2 (es) Composiciones pharmaceuticas que comprenden alisporivir
IN2014DN10209A (es)
UY33207A (es) Métodos de preparación de tiazolidinas
TR201107233U (tr) Pratik fal bakma fincanında geliştirme.
TR201112564U (tr) Ayarlı besimatik.
TR201000550U (tr) Saksı ağzının içeriye doğru kıvrılmasının sağlayan yapılanma.

Legal Events

Date Code Title Description
FG Grant or registration